Share on StockTwits

Chimerix (NASDAQ:CMRX) CFO Timothy W. Trost sold 5,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $18.26, for a total transaction of $91,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Piper Jaffray initiated coverage on shares of Chimerix in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $33.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $257.75.

Chimerix (NASDAQ:CMRX) traded up 3.25% during mid-day trading on Tuesday, hitting $18.75. The stock had a trading volume of 138,097 shares. Chimerix has a 52 week low of $12.96 and a 52 week high of $27.00. The stock has a 50-day moving average of $16.28 and a 200-day moving average of $17.78. The company’s market cap is $495.4 million.

Chimerix (NASDAQ:CMRX) last released its earnings data on Thursday, November 14th. The company reported ($0.26) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.38) by $0.12. Analysts expect that Chimerix will post $-2.57 EPS for the current fiscal year.

Chimerix, Inc is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.